ADVIESBEHEER GIMV LIFE SCIENCES NV 4

Accession 0001284391-09-000003

CIK 0001070698other

View on SEC.gov Company Profile

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 10:50 AM ET

Size

24.7 KB

Accession

0001284391-09-000003

Insider Transaction Report

Form 4

Period: 2009-09-17

Raptor Pharmaceutical CorpRPTD

GIMV NV

Other

Transactions

Sale
Common stock
2009-09-17$0.27/sh−54,022$14,602→ 1,490,381 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−6,778$1,832→ 186,998 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−17,211$4,306→ 139,084 total(indirect: See footnote)
Sale
Common stock
2009-09-18$0.26/sh−75,689$19,974→ 385,306 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−42,430$10,616→ 342,876 total(indirect: See footnote)
Sale
Common stock
2009-09-18$0.26/sh−244,699$64,576→ 1,245,682 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−16,710$4,517→ 460,994 total(indirect: See footnote)
Sale
Common stock
2009-09-18$0.26/sh−30,702$8,102→ 156,296 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−137,715$34,456→ 1,108,507 total(indirect: See footnote)

ADVIESBEHEER GIMV LIFE SCIENCES NV

Other

Transactions

Sale
Common stock
2009-09-18$0.26/sh−30,702$8,102→ 156,296 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−17,211$4,306→ 139,084 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−137,715$34,456→ 1,108,507 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−54,022$14,602→ 1,490,381 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−42,430$10,616→ 342,876 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−6,778$1,832→ 186,998 total(indirect: See footnote)
Sale
Common stock
2009-09-18$0.26/sh−244,699$64,576→ 1,245,682 total(indirect: See footnote)
Sale
Common stock
2009-09-18$0.26/sh−75,689$19,974→ 385,306 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−16,710$4,517→ 460,994 total(indirect: See footnote)

Biotech Fonds Vlaanderen NV

Other

Transactions

Sale
Common stock
2009-09-18$0.26/sh−244,699$64,576→ 1,245,682 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−17,211$4,306→ 139,084 total(indirect: See footnote)
Sale
Common stock
2009-09-18$0.26/sh−75,689$19,974→ 385,306 total(indirect: See footnote)
Sale
Common stock
2009-09-18$0.26/sh−30,702$8,102→ 156,296 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−16,710$4,517→ 460,994 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−137,715$34,456→ 1,108,507 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−6,778$1,832→ 186,998 total(indirect: See footnote)
Sale
Common stock
2009-09-17$0.27/sh−54,022$14,602→ 1,490,381 total(indirect: See footnote)
Sale
Common stock
2009-09-21$0.25/sh−42,430$10,616→ 342,876 total(indirect: See footnote)

Footnotes (6)

[F1]Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was $0.2700 to $0.2770 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each seperate price.
[F2]The reported securities are directly held by Gimv NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary intrest herein.
[F3]The reported securities are directly held by Adviesbeheer Gimv Life Sciences NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary intrest herein.
[F4]The reported securities are directly held by Biotech Fonds Vlaanderen NV. The reporting person on this Form 4 disclaims beneficial ownership of the reported securities except to the extent of his pecuniary intrest herein.
[F5]Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was $0.2600 to $0.2800 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each seperate price.
[F6]Price reflected is the weighted-average sale price for the Torreypines Therapeutics shares sold. The range of sale prices for the transactions reported was $0.2500 to $0.2550 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each seperate price.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT

Issuer

Raptor Pharmaceutical Corp

CIK 0001070698

→

Entity typeother

Related Parties

filerCIK 0001284392

Filing Metadata

Form type: 4
Filed: Sep 30, 8:00 PM ET
Accepted: Oct 1, 10:50 AM ET
Size: 24.7 KB

View on SEC.gov